

Handbook of Medical Treatment

Seventeenth Edition

Edited by
H. David Watts, MD
University of California, San Francisco



JONES MEDICAL PUBLICATIONS
Greenbrae, California

Copyright © 1983
JONES MEDICAL PUBLICATIONS
355 Los Cerros Drive, Greenbrae, CA 94904

JMP Handbook Series
Handbook of Surgery, 7th Edition
Theodore R. Schrock, MD (Editor)

All rights reserved. No part of this book may be reproduced in any manner without the written permission of the publisher.

Previous editions copyrighted © 1949, 1951, 1953, 1954, 1956, 1958, 1960, 1962, 1964, 1966, 1968, 1970, 1972, 1974 by Lange Medical Publications, Los Altos, California. © 1977 and 1979 by Jones Medical Publications.

Library of Congress Catalog Card Number:
62-13251

ISBN: 0-930010-07-8

Printed in the United States of America
987654321

Handbook
of
Medical Treatment

Preface

Handbook of Medical Treatment is an up-to-date compendium intended as a first reference for students, practising physicians, and all health care professionals.

Selection of material and extent of coverage are major problems whenever attempts are made to encapsulate large bodies of knowledge in an easily retrievable form — we hope we have succeeded to some useful degree in this endeavor.

In this the seventeenth edition a major revision has taken place in order to more fully satisfy the demands of the fast-moving fields in medicine. We welcome many new authors and sincerely thank all the eminent practitioners who have been associated with this work in the past. We hope this edition will continue to be as valuable to student and practitioner as have all the previous editions.

I am indebted to the authors for their careful, clear contributions and to Richard Jones for his steadfast support and guidance.

H. David Watts, MD

San Francisco, California
January, 1983

NOTICE

The authors and the editor have endeavored to recommend drugs and dosages that are in agreement with recognized medical standards at the time of publication. All clinicians are urged to review drug manufacturers' current product information (e.g., package inserts) especially in the case of new and infrequently prescribed medication. The clinician should be sufficiently familiar with each drug prescribed so that the drug can be used to greatest therapeutic advantage, while minimizing the possibility of undesirable adverse effects.

Authors

Except where noted the authors are affiliated with the Medical School of the University of California, San Francisco.

- Michael J. Aminoff, MD *Associate Professor of Neurology*
Clifford H. Berken, MD *Department of Medicine, Harvard Medical School*
James K. Brown, MD *Assistant Professor of Medicine*
Kanu Chatterjee, MB, FRCP *Professor of Medicine*
Milton J. Chatton, MD *Clinical Professor of Medicine, Stanford University School of Medicine*
John M. Erskine, MD *Associate Clinical Professor of Surgery*
Paul A. Fitzgerald, MD *Assistant Clinical Professor of Medicine*
Michael A. Friedman, MD *Assistant Professor of Medicine*
Kenneth A. Fye, MD *Assistant Clinical Professor of Medicine*
Kenneth D. Gardner, Jr., MD *Professor of Medicine, University of New Mexico School of Medicine, Albuquerque*
Robert S. Goldsmith, MD, DTM&H *Associate Professor of Tropical Medicine*
John L. Gollan, MD, PhD *Associate Professor of Medicine, Harvard Medical School*
Julien I. E. Hoffman, MD *Professor of Pediatrics and Physiology*
Ernest Jawetz, MD, PhD *Professor of Microbiology and Medicine*
John H. Karam, MD *Associate Professor of Medicine*
Gideon Letz, MD, MPH *State of California, Department of Health Services*
James L. Naughton, MD *Assistant Professor of Medicine*
Marion Nestle, PhD *Associate Dean, School of Medicine*
Kent R. Olson, MD *Clinical Pharmacology & Toxicology Service, San Francisco General Hospital*
Rees B. Rees, MD *Clinical Professor of Dermatology, Emeritus*
Curt A. Ries, MD *Associate Clinical Professor of Medicine*
Kenneth E. Sack, MD *Assistant Professor of Medicine*
Melvin M. Scheinman, MD *Professor of Medicine*
Maurice Sokolow, MD *Professor of Medicine, Emeritus*
Michael S. Stulberg, MD *Assistant Clinical Professor of Medicine*
Theodore G. Tong, PharmD *College of Pharmacy, University of Arizona, Tucson*
Donald Trunkey, MD *Professor of Surgery*
H. David Watts, MD *Assistant Professor of Medicine*

Contents

Preface	vii
Authors.	ix
1. Shock, Trauma, & General Symptoms	1
Donald Trunkey and Milton J. Chatton	
2. Fluid & Electrolyte Disorders	36
James L. Naughton	
3. Renal Disease	58
Kenneth D. Gardner, Jr.	
4. Respiratory Failure	74
James K. Brown	
5. Respiratory Diseases	83
Michael S. Stulbarg and James K. Brown	
6. Ischemic Heart Disease	97
Kanu Chatterjee	
7. Cardiomyopathy & Pericardial Disorders	118
Kanu Chatterjee and Julien I. E. Hoffman	
8. Hypertension	130
Maurice Sokolow	
9. Cardiac Arrhythmias	137
Melvin M. Scheinman	
10. Valvular Heart Disease.	149
Maurice Sokolow	
11. Diseases of Blood Vessels	163
John Erskine	
12. Hematologic Diseases	175
Curt A. Ries	
13. Cancer Chemotherapy	206
Michael A. Friedman	
14. Gastrointestinal Bleeding	217
H. David Watts	

15. Gastrointestinal Disorders	224
H. David Watts	
16. Hepatobiliary Disorders	241
John L. Gollan and Clifford A. Berken	
17. Nutritional Support	257
Marion Nestle	
18. Diabetes Mellitus	283
John H. Karam	
19. Endocrine & Metabolic Disorders	297
Paul A. Fitzgerald	
20. Infectious Diseases	326
Ernest Jawetz	
21. Antimicrobial Drugs	349
Ernest Jawetz	
22. Parasitic Diseases	371
Robert S. Goldsmith	
23. Neurologic Disorders	380
Michael J. Aminoff	
24. Arthritis & Related Disorders	408
Kenneth H. Fye and Kenneth E. Sack	
25. Skin Disorders	423
Rees B. Rees	
26. Acute Toxic Exposures	440
Gideon Letz, Theodore G. Tong, and Kent R. Olson	
Appendix	455
Cardiopulmonary Resuscitation 455	
Emergency Treatment of Food Choking 459	
Desirable Weight Tables 460	
Normal Laboratory Values 461	
Index	465

1 Shock, Trauma, & General Symptoms

Donald Trunkey, MD

SHOCK

Shock is defined as peripheral circulatory failure causing tissue perfusion to be inadequate to meet the nutritional requirements of the cells and remove the waste products of metabolism. In the simplest terms, therefore, shock is inadequate tissue perfusion.

Shock may be classified as hypovolemic, septic, cardiogenic, neurogenic, or miscellaneous (e.g., anaphylactic reactions and insulin shock).

HYPOVOLEMIC SHOCK

This is the result of decreased blood volume due to acute and severe loss of blood, plasma, or body water and electrolytes. Hemorrhage, burns, bowel obstruction, peritonitis, and crush injuries are some of the common causes. A fall in venous pressure, a rise in peripheral vascular resistance, and tachycardia are characteristic of hypovolemic shock.

Factors that make a patient especially susceptible to hypovolemic shock include: age (the very young and the elderly tolerate loss of body water or plasma poorly); chronic illness (such patients often have a reduced blood volume and relatively small acute losses may precipitate shock); anesthesia (paralysis of vasomotor tone may cause shock in a patient who has compensated for a reduced blood volume); adrenal insufficiency (profound hypotension may be induced by minimal stress if corticosteroids are not supplied during and after trauma, operation, or illness).

A. PATHOPHYSIOLOGY Events in the microcirculation progress in phases.

1. Compensation phase The first response of the circulation to hypovolemia is contraction of the precapillary arterial sphincters; this causes the filtration pressure in the capillaries to fall. Since osmotic pressure remains the same, fluid moves into the vascular space with a corresponding increase in blood volume. If this compensatory mechanism is adequate to return blood volume to normal, the capillary sphincters relax and microcirculatory flow returns to normal. If shock is prolonged and profound, the next phase is entered.

2. Cell distress phase If vascular volume has not been restored, the precapillary sphincters remain closed, and arteriovenous shunts open up to divert arterial blood directly back into the venous system, thus maintaining circulation to more important organs such as the heart and brain. The cells in the bypassed segment of the microcirculation must rely on anaerobic metabolism for energy. The amount of glucose and oxygen available for the cell decreases, and metabolic waste products such as lactate accumulate. Histamine is released, resulting in closure of the postcapillary sphincters, and this mechanism serves to slow the remaining capillary flow and hold the red blood cells and nutrients in the capillaries longer. The empty capillary bed constricts almost completely; very few capillaries remain open.

3. Decompensation phase Just before cell death, local reflexes (probably initiated by acidosis and accumulated metabolites) reopen the precapil-

lary sphincters while the postcapillary sphincters stay closed. Prolonged vasoconstriction of the capillary bed damages endothelial cells and results in increased capillary permeability. When the capillaries finally reopen, fluid and protein are leaked into the interstitial space, the capillaries distend with red blood cells, and sludging occurs. Cells become swollen, they are unable to utilize oxygen, and they die.

4. Recovery phase If blood volume is restored at some point in the decompensation phase, the effects on the microcirculation may still be reversible. Badly damaged cells may recover, and capillary integrity may be regained. The 'sludge' in the microcirculation is swept into the venous circulation and eventually into the lungs where these platelet and white cell aggregates are filtered out and produce postshock pulmonary failure. Other capillaries may be so badly damaged and filled with sludge that they remain permanently closed; cells dependent upon these capillaries die.

Table 1-1 Clinical classification of hypovolemic shock

Mild shock (up to 20% blood volume loss)

Definition: Decreased perfusion of nonvital organs and tissues (skin, fat, skeletal muscle, and bone).

Manifestations: Pale, cool skin. Patient complains of feeling cold.

Moderate shock (20-40% blood volume loss)

Definition: Decreased perfusion of vital organs (liver, gut, kidneys)

Manifestations: Oliguria to anuria and slight to significant drop in blood pressure.

Severe shock (40% or more blood volume loss)

Definition: Decreased perfusion of heart and brain.

Manifestations: Restlessness, agitation, coma, cardiac irregularities, ECG abnormalities, and cardiac arrest.

Reproduced with permission from Dunphy JE, Way LW (eds): *Current Surgical Diagnosis & Treatment*, 3rd Ed. Lange 1977.

B. DIAGNOSIS Clinical assessment permits classification of hypovolemic shock as mild, moderate, or severe (Table 1-1). The compensatory mechanisms act to preserve blood flow to the heart and brain at the expense of all others; thus, in severe shock, there is marked constriction of all other vascular beds.

C. TREATMENT Shock is an acute emergency: **act promptly!**

1. Keep the patient recumbent—do not move the patient unnecessarily.

2. Establish and maintain an airway.

3. Place one or more large intravenous catheters.

a. Do a cutdown in the long saphenous vein at the ankle; this method is rapid and safe.

b. Do a cutdown on the basilic vein in the antecubital space so that central venous pressure can be monitored.

c. Percutaneous insertion of subclavian or jugular catheters is not recommended because the veins are collapsed in hypovolemic shock. Femoral vein catheters may be placed percutaneously in unusual circumstances, e.g., when a single physician is available for resuscitation.

4. **Parenteral fluids** Begin immediately to restore blood volume. In mild or moderate shock, it makes little difference which fluid is used (Table 1-2). In severe shock, the choice of fluid is important because endothelial permeability may be increased or microvascular forces altered, resulting in 'capillary leak' which compounds the problems if colloid is given.

a. Crystalloids are preferred in the initial treatment of shock. They are readily available and effectively restore vascular volume for brief periods. Crystalloids also lower blood viscosity and enhance resuscitation of the microcirculation. Balanced salt solutions plus judicious amounts of sodium bicarbonate correct the acidosis which invariably is present in shock. Serial blood pH measurements are a guide. Overcorrection of acidosis is more harmful than the opposite.

b. Colloids

(1) *Blood* is available in emergencies as low-titer O negative or type-specific. O negative blood has the theoretical disadvantage of isoimmunization or difficulty with typing and cross-matching later; this is probably not a major consideration. Type-specific blood can be used until crossmatched blood becomes available (about 45 minutes).

If shock persists after 2 liters of crystalloid have been infused, or if shock recurs after the patient initially responds, whole blood should be transfused immediately.

(2) *Albumin solutions* are detrimental in prolonged severe shock. These substances leak through capillary membranes taking water with them, thus exacerbating pulmonary interstitial edema. *Plasma* should be given if specific coagulation defects occur such as factors V and VII (usually dilutional).

(3) *Plasma substitutes* (dextran) interfere with function of the reticulo-endothelial system and depress the already impaired immune mechanisms in shock patients. Clinical dextran coats red cells, making typing and crossmatching difficult; low molecular weight dextran coats platelets and may contribute to bleeding.

5. The underlying cause of shock should be investigated and treated while resuscitation is underway. Failure of resuscitation almost always reflects persistent massive hemorrhage, and definitive operative treatment offers the only chance for survival.

6. Evaluation of treatment The amount of fluid that a patient should receive is governed by the patient's response; there is no rigid formula. Constant close monitoring is essential (see Table 1-3). Atrial filling pressure and urine output are the most useful signs.

a. Left atrial filling pressure is rarely measured directly, but the pulmonary artery wedge pressure is a useful approximation, and it should be monitored in critical patients. Central venous pressure is sufficiently accurate in the majority of patients. In mild or moderate shock, resuscitation may be permitted to raise atrial filling pressure as high as 20 torr without risk. In severe shock, however, atrial filling pressure must be kept at or near normal (3-8 torr) because higher pressures aggravate interstitial edema.

b. Urine output should be monitored; this usually requires a urinary catheter. Urine output greater than 0.5 cc/kg/hour is a good index of visceral blood flow, specifically renal blood flow.

c. Additional signs of successful resuscitation include an alert, oriented patient and adequate peripheral perfusion as judged by clinical criteria.

d. Blood pressure, pulse rate, and respiratory rate should be recorded every 15-30 minutes.

e. Hematocrit should be measured every few hours if continued bleeding is suspected. The hematocrit usually falls gradually over a period of 24-48 hours because of hemodilution even if bleeding has stopped.

f. Blood gases should be determined repeatedly (see Table 1-3).

g. Other measurements, obtained in certain circumstances, include cardiac output and oxygen consumption.

5. Failures of resuscitation

a. If both atrial filling pressure and urine output are increased, too much fluid is being given, and the infusion rate should be slowed immediately.

b. If both atrial filling pressure and urine output are below normal, more volume is required.

Table 1-2 Fluid resuscitation of shock

I. Crystalloids

- A. Isotonic sodium chloride
- B. Hypertonic sodium chloride
- C. Balanced salt solution
 - 1. Ringer's lactate
 - 2. *Ringer's acetate*
 - 3. Normosol, Plasmolyte, etc.

II. Colloid

- A. Blood
 - 1. Low-titer O negative blood
 - 2. *Type-specific*
 - 3. Typed and crossed
 - 4. Washed red cells
 - 5. Fresh red cells
- B. Plasma and its components
 - 1. Plasma—fresh frozen
 - 2. Albumin
 - 3. Plasmanate
- C. Plasma substitutes
 - 1. Clinical dextran (M.W. 70,000)
 - 2. Low molecular weight dextran (M.W. 40,000)

Table 1-3 Variables frequently monitored in shock

Measurement	Typical normal values	Typical values in severe shock
Arterial blood pressure	120/180	< 90 mm Hg systolic
Pulse rate	80/minute	> 100/minute
Central venous pressure	4–8 cm saline	< 3 cm
Hematocrit	35–45%	< 35%
Arterial blood:		
pH	7.4	7.3
pO ₂	95 mm Hg	85 mm Hg
pCO ₂	40 mm Hg	< 30 mm Hg
-HCO ₃	23–25 mEq/liter	< 23 mEq/liter
Lactic acid	12 mg/100 ml	> 20 mg/100 ml
Urine:		
Volume	50 ml/hour	< 20 ml/hour
Specific gravity	1.015–1.025	> 1.025
Osmolality	300–400 mOsm/kg water	> 700 mOsm/kg water

c. When atrial filling pressure is elevated and urine output is low, measurement of cardiac output is useful.

- (1) High atrial filling pressure, low urine output, and high or normal cardiac output indicate deficient renal function. This may be documented by urine/plasma ratios of creatinine, sodium, and osmolarity. Give mannitol (12.5-25 gm IV) followed by infusion of mannitol 50 gm in 500-1000 ml of balanced salt solution. No more than 75-100 gm of mannitol should be given.
- (2) High atrial filling pressure, low urine output, and low cardiac output suggest that an inotropic agent is needed (Table 1-4). (i) *Dopamine hydrochloride*, 200 mg in 500 ml of sodium injection USP (400 μ g/ml), is given initially at a rate of 2.5 μ g/kg/minute. These doses stimulate both the dopaminergic receptors, which increase the renal blood flow and urine output, and the beta adrenergic cardiac receptors, which increase the cardiac output. Higher levels stimulate alpha receptors to cause systemic vasoconstriction, and doses above 20 μ g/kg/minute reverse the vasodilatation of the renal vessels achieved at lower levels. (ii) *Isoproterenol*, a beta-adrenergic stimulator, increases cardiac output by its action on the myocardial contraction mechanism, and it also produces peripheral vasodilatation. Give 1-2 mg in 500 ml of 5% dextrose in water IV. Isoproterenol should not be used if the heart rate is greater than 100-120/minute lest cardiac arrhythmias develop. (iii) *10% calcium chloride* (10 cc) may be administered directly IV over 2-3 minutes provided there is continuous cardiac monitoring for arrhythmias. Although calcium may produce an instant inotropic effect, it is usually not sustained, and repeated doses are required. Measurement of ionized calcium levels are prudent in such instances.

d. There is no convincing evidence that corticosteroids or ganglionic blocking drugs are of value in hypovolemic shock.

SEPTIC SHOCK

This is most often due to gram-negative septicemia, although infection by gram-positive bacteria can also cause shock. Trauma, diabetes mellitus, hematologic diseases, corticosteroid therapy, immunosuppressive drugs, and radiation therapy increase susceptibility to infection and thus predispose to septic shock. Precipitating events are often operations on the urinary, biliary, or gynecologic systems.

A. PATHOPHYSIOLOGY

1. **Gram-negative septicemia** causes a generalized increase in capillary permeability, loss of fluid from the vascular space, and pooling of blood in the microcirculation. All of these mechanisms contribute to hypovolemia. There may also be a direct toxic effect on the heart, with depression of myocardial function. Peripheral vascular resistance usually is lowered as the result of arteriovenous shunting.

2. **Gram-positive septicemia** occasionally produces hypovolemia, but the loss of fluid from the vascular space usually is limited to the area of infection.

3. **Disseminated intravascular coagulation (DIC)** may develop in septic shock.

B. DIAGNOSIS

1. **Symptoms and signs** (1) The inciting infection may be obscure. (2) Confusion and restlessness are early indications. (3) The skin is warm and the pulses full initially; vasoconstriction develops later. (4) Pulmonary hypertension and hyperventilation. (5) Urine output is normal at first, then it slows rapidly.

2. **Laboratory tests** (1) Inability to metabolize glucose (glycosuria, hyperglycemia) is an early finding. (2) Respiratory alkalosis. (3) Hemocon-

Table 1-4 Adrenergic drugs used in hypotensive states.
(Effects graded on a scale of 0-5)

Drug	Vasomotor Effect		Cardiac Stimulant (Inotropic Effect)	Cardiac Output	Renal and Splanchnic Blood Flow
	Vaso-constriction	Vaso-dilatation			
Alpha-adrenergic					
Phenylephrine (Neo-Synephrine)	5	0	0	Reduced	Reduced
Mixed alpha- and beta-adrenergic					
Norepinephrine (Levophed)	4	0	2	Reduced	Reduced
Metaraminol (Aramine)	3	2	1	Reduced	Reduced
Epinephrine (Adrenalin)	4	3	4	Increased	Reduced
Dopamine (Intropin)*	2	2	2	Usually increased	Increased
Beta-adrenergic					
Isoproterenol (many trade names)	0	5	4	Increased	Usually reduced

*Claimed to have a special (dopaminergic) receptor.

Reproduced with permission from Krupp, MA, Chatton, MJ (Eds.): *Current Medical Diagnosis & Treatment*. Lange, 1977.

Table 1-5 Biochemical and metabolic effects of corticosteroids

-
1. ↑ Hepatic glucose output
 2. Hyperaminoacidemia
 3. ↑ Secretion of glucagon
 4. Inhibition of lipogenesis—selective
 5. Induces negative calcium balance
 6. Blocks ↑ capillary endothelial permeability
 7. Markedly inhibits exudation of inflammatory cells
 8. May maintain plasma membrane integrity
 9. Suppresses T helper cell
 10. Stabilizes lysosome membrane
 11. Exhibits myocardial inotropism
-

centration is common. (4) Early leukopenia followed by leukocytosis; usually the leukocyte count is 15,000 or more with a shift to the left. (5) Identification of the responsible organism(s) is urgent. Obtain cultures on samples of blood, sputum, urine, drainage fluid, and any other suspicious site. A gram-stained smear of infected fluid may suggest the origin of the problem and guide emergency therapy.

C. TREATMENT As in other forms of shock, the objective of treatment is to improve tissue perfusion. In addition, the underlying infection must be treated.

1. Volume replacement The initial fluid should be balanced salt solution; colloids are particularly prone to leak from capillaries and aggravate interstitial edema in septic shock. Fluid volume is adjusted by close monitoring as described for hypovolemic shock.

2. Antibiotic therapy Large doses of specific antibiotics should be given if the organism is known; if not a 'best guess' should be made as to the responsible bacteria, and antibiotics are given accordingly (see Table 21-3).

3. Surgical drainage If an abscess or other accessible focus of infection is identified, it should be drained, debrided, or decompressed promptly. Antibiotics and fluid resuscitation will not salvage the patient if the source of infection is not found and drained.

4. Supportive measures Close attention should be paid to maintenance of ventilation. Accompanying disorders must be treated. If the patient continues to deteriorate, cardiovascular support with inotropic agents may be required as in hypovolemic shock.

5. Corticosteroid therapy Corticosteroids have both beneficial and deleterious effects in septic shock (Tables 1-5 and 1-6). Because the disadvantages outweigh the advantages, the use of corticosteroids in septic shock cannot be recommended.

Table 1-6 Acute complications of corticosteroid therapy in the shock patient

-
1. Peptic ulceration
 2. Intestinal perforation
 3. Pancreatitis
 4. Sodium and water retention
 5. Impaired wound healing
 6. Suppression of the immune response
-

CARDIOGENIC SHOCK

Some degree of cardiac failure, usually left ventricular, can be detected in 20-50% of patients with acute myocardial infarction.

A. DIAGNOSIS Clinical findings are often absent or minimal. Dyspnea, pulmonary rales, diastolic gallop, accentuated pulmonary second sound, pulsus alternans, and pulmonary venous congestion on chest x-ray may or may not be present. The radiographic changes take time to develop and are slow to resolve, so they are not very helpful acutely. Hypotension is often the first sign that cardiac failure is more severe than suggested by the other parameters.

B. TREATMENT

1. Treatment of mild left ventricular failure consists of oral diuretics (e.g., hydrochlorothiazide 50-100 mg), oxygen, and limitation of sodium intake.

2. More aggressive treatment is required for severe left ventricular failure. Such patients should have monitoring of arterial pressure, pulmonary artery wedge pressure, and cardiac output. The stroke work index can be computed, and rational therapy is based on the specific hemodynamic abnormality found.

a. Low left ventricular filling pressure (less than 2 torr), normal cardiac output, and low arterial pressure indicate hypovolemia. Replace volume, beginning with 100 ml of saline or balanced salt solution. If cardiac output does not increase as left ventricular filling pressure rises to 15-20 torr, stop volume replacement to avoid pulmonary edema which may occur abruptly.

b. Elevated left ventricular filling pressure, normal cardiac output, and normal blood pressure suggest that vigorous diuresis should be attempted with large doses of furosemide. Avoid volume depletion from excessive diuresis.

c. Normal left ventricular filling pressure, normal cardiac output, and low arterial pressure reflect a failure of compensatory peripheral vasoconstriction. Give epinephrine or dopamine to stimulate beta-adrenergic receptors. These drugs should be infused slowly to avoid tachycardia, hypertension, and ventricular arrhythmias. The goal is to maintain blood pressure but not increase the stroke work index.

d. Elevated left ventricular filling pressure (more than 20 torr), low cardiac output, and arterial blood pressure at or above 90 torr, is a pattern for which vasodilator therapy can be given. Drugs such as sodium nitroprusside, phentolamine, or nitroglycerine infused slowly IV, decrease the impedance to left ventricular ejection. Reduced left ventricular volume and filling pressure may improve the left ventricular stroke work index, lower the myocardial oxygen consumption (MVO_2), and improve perfusion to the brain, heart, and kidneys. The arterial blood pressure should be 90 torr or more before vasodilators can be given safely; if vasopressors cannot be used to raise blood pressure without elevating left ventricular filling pressure and aggravating cardiac failure, aortic balloon counter pulsation may be useful as a temporary aid to make vasodilator therapy possible.

NEUROGENIC SHOCK

Neurogenic shock is due to a failure of arterial resistance from nervous or psychic stimulation (e.g., sudden pain or fright), vasodilator drugs (nitrites), spinal anesthesia, or spinal trauma. Blood pools in dilated capacitance vessels, and blood pressure falls. Cardiac activity increases to fill the dilated vascular bed and preserve tissue perfusion.

Prodromal symptoms and signs are pallor, cold sweat, weakness, light-headedness, and occasionally nausea. Fainting is accompanied by transient hypotension and bradycardia.

Neurogenic shock is self-limiting. Resting in a recumbent or head-down position with the legs elevated for a few minutes is usually sufficient. If the patient is sitting down, and reclining is not possible, have him bend forward